+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

I

Actively Recruiting

Healthy Volunteer

Accidental hypothermia, especially severe cases with core body temperatures below 28C, can be life-threatening and often results from accidents like snow sports, near drowning, or urban cold exposure. Researchers aim to better understand the causes, treatment methods, and complications of accidental hypothermia through the International Hypothermia Registry. This observational study collects worldwide data to improve knowledge on patient outcomes and treatment approaches. The study gathers detailed information on accidental hypothermia cases, including prehospital and hospital treatments, rewarming techniques, and patient outcomes. Both prospective and retrospective cases are included without limits on the year of occurrence. The registry collects data through a comprehensive questionnaire covering demographics, clinical status, treatments, and outcomes. Participants provide information during and after treatment, with data recorded in a secure database over an average follow-up of one year. Researchers analyze these data to identify survival predictors, optimal rewarming methods, and ways to prevent complications after rewarming. The registry aims to develop evidence-based guidelines for diagnosing and treating accidental hypothermia to improve patient care worldwide.

All AgesAll Genders
16 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of adagrasib MRTX849 alone and combined with pembrolizumab in patients with advanced or metastatic non-small cell lung cancer NSCLC who have a KRAS G12C mutation. The study includes both Phase 2 and Phase 3 portions, focusing on patients eligible for first-line treatment with varying levels of PD-L1 expression. The trial compares adagrasib combined with pembrolizumab to pembrolizumab alone in patients with high PD-L1 expression. In Phase 2, patients are divided into three groups based on PD-L1 TPS scores two groups with scores below 1% receive either adagrasib monotherapy or adagrasib plus pembrolizumab, and one group with scores of 1% or higher receives the combination. Phase 3 randomizes patients with PD-L1 TPS of 50% or higher to receive either adagrasib plus pembrolizumab or pembrolizumab alone. Adagrasib is taken orally twice daily, while pembrolizumab is given intravenously every three weeks. Participants undergo regular assessments including brain imaging, tumor measurements, and quality of life questionnaires. Researchers monitor treatment effects, safety, drug levels in blood, and lung cancer symptoms over periods of up to 22 months in Phase 2 and 36 months in Phase 3. The study also evaluates progression-free survival, response duration, and other outcomes to understand the treatments impact.

Age: 18Years +All GendersPhase 2Phase 3
770 locations
O

Actively Recruiting

This observational study evaluates the Minos4 Abdominal Aortic Stent-Graft and Delivery System, a medical device used to treat abdominal aortic aneurysms through a minimally invasive procedure. The device is inserted into the aorta via blood vessels, typically through small groin incisions. The study aims to collect short-, medium-, and long-term safety and performance data from about 200 patients worldwide, including at least 30 patients in European hospitals. Participants in this study will be treated with the Minos4 stent-graft system as part of their usual medical care. The treatment involves implanting the device to repair the aneurysm, with follow-up care conducted according to each institutions standard practices. The study focuses on real-world use of the device, observing outcomes over time. During the study, participants will be monitored for technical success at 12 months and assessed for various outcomes such as adverse events within 30 days, aneurysm treatment success over 2 to 5 years, mortality rates, secondary interventions, aneurysm size changes, and device-related complications. This follow-up can continue for up to five years after the procedure to gather comprehensive safety and performance information.

Age: 18Years +All Genders
16 locations